Inhibitor potency and assay conditions: a case study on SARS-CoV-2 main protease
Li et al. (1) report known drugs as inhibitors of the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The compounds, including atazanavir, were initially identified by virtual screening, followed by fluorescence resonance energy transfer (FRET)-based biochemical...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2, 2021
|
| In: |
Proceedings of the National Academy of Sciences of the United States of America
Year: 2021, Jahrgang: 118, Heft: 36, Pages: 1-2 |
| ISSN: | 1091-6490 |
| DOI: | 10.1073/pnas.2106095118 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1073/pnas.2106095118 Verlag, lizenzpflichtig, Volltext: https://www.pnas.org/content/118/36/e2106095118 
|
| Verfasserangaben: | Mira A.M. Behnam and Christian D. Klein |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1777654831 | ||
| 003 | DE-627 | ||
| 005 | 20230426124510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211117s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2106095118 |2 doi | |
| 035 | |a (DE-627)1777654831 | ||
| 035 | |a (DE-599)KXP1777654831 | ||
| 035 | |a (OCoLC)1341424022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Behnam, Mira A. M. |e VerfasserIn |0 (DE-588)1060575957 |0 (DE-627)800333284 |0 (DE-576)416731252 |4 aut | |
| 245 | 1 | 0 | |a Inhibitor potency and assay conditions |b a case study on SARS-CoV-2 main protease |c Mira A.M. Behnam and Christian D. Klein |
| 264 | 1 | |c September 2, 2021 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.11.2021 | ||
| 520 | |a Li et al. (1) report known drugs as inhibitors of the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The compounds, including atazanavir, were initially identified by virtual screening, followed by fluorescence resonance energy transfer (FRET)-based biochemical inhibition assays. - - In this letter, we demonstrate that the inhibitory activity achieved in enzymatic assays by the compounds is sensitive to the conditions used. This observation supports the proposed conformational selection paradigm for SARS-CoV-2 Mpro (2). - - Using an Mpro with C-terminal His-tag and the FRET substrate Abz-VVTLQ/SGDap(Dnp)R-OH (3), atazanavir showed no or minimal inhibition under all studied conditions, including the buffer used by Li et al. (1) This point was previously raised by Ma and Wang (4), and, in comparison to their substrate Dabcyl-KTSAVLQ/SGFRKME(Edans) (5), our shorter substrate renders an influence of substrate length less likely and pinpoints the difference in … To whom correspondence may be addressed. Email: mira.behnamuni-heidelberg.de or c.klein{at}uni-heidelberg.de. | ||
| 700 | 1 | |a Klein, Christian D. |e VerfasserIn |0 (DE-588)1060644894 |0 (DE-627)800410157 |0 (DE-576)416768717 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a National Academy of Sciences (Washington, DC) |t Proceedings of the National Academy of Sciences of the United States of America |d Washington, DC : National Acad. of Sciences, 1915 |g 118(2021), 36, Artikel-ID e2106095118, Seite 1-2 |h Online-Ressource |w (DE-627)254235379 |w (DE-600)1461794-8 |w (DE-576)073260509 |x 1091-6490 |7 nnas |
| 773 | 1 | 8 | |g volume:118 |g year:2021 |g number:36 |g elocationid:e2106095118 |g pages:1-2 |g extent:2 |a Inhibitor potency and assay conditions a case study on SARS-CoV-2 main protease |
| 856 | 4 | 0 | |u https://doi.org/10.1073/pnas.2106095118 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.pnas.org/content/118/36/e2106095118 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211117 | ||
| 993 | |a Editorial | ||
| 994 | |a 2021 | ||
| 998 | |g 1060644894 |a Klein, Christian D. |m 1060644894:Klein, Christian D. |d 160000 |d 160100 |e 160000PK1060644894 |e 160100PK1060644894 |k 0/160000/ |k 1/160000/160100/ |p 2 |y j | ||
| 999 | |a KXP-PPN1777654831 |e 4002740617 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Mira A. M.","display":"Behnam, Mira A. M.","family":"Behnam"},{"display":"Klein, Christian D.","family":"Klein","role":"aut","given":"Christian D."}],"recId":"1777654831","relHost":[{"pubHistory":["1.1915 -"],"recId":"254235379","language":["eng"],"title":[{"title":"Proceedings of the National Academy of Sciences of the United States of America","title_sort":"Proceedings of the National Academy of Sciences of the United States of America"}],"note":["Gesehen am 09.03.2022"],"disp":"National Academy of Sciences (Washington, DC)Proceedings of the National Academy of Sciences of the United States of America","titleAlt":[{"title":"PNAS online"},{"title":"PNAS"}],"part":{"volume":"118","text":"118(2021), 36, Artikel-ID e2106095118, Seite 1-2","issue":"36","year":"2021","extent":"2","pages":"1-2"},"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1091-6490"],"eki":["254235379"],"zdb":["1461794-8"]},"corporate":[{"display":"National Academy of Sciences","role":"aut"}],"origin":[{"publisherPlace":"Washington, DC","dateIssuedDisp":"1915-","publisher":"National Acad. of Sciences","dateIssuedKey":"1915"}]}],"title":[{"title_sort":"Inhibitor potency and assay conditions","subtitle":"a case study on SARS-CoV-2 main protease","title":"Inhibitor potency and assay conditions"}],"note":["Gesehen am 17.11.2021"],"language":["eng"],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"September 2, 2021"}],"physDesc":[{"extent":"2 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Mira A.M. Behnam and Christian D. Klein"]},"id":{"doi":["10.1073/pnas.2106095118"],"eki":["1777654831"]}} | ||
| SRT | |a BEHNAMMIRAINHIBITORP2202 | ||